Angion Biomedica Corp. (ANGN)
$1
0.00 (0.00%)
Rating:
Recommendation:
-
| Symbol | ANGN |
|---|---|
| Price | $1 |
| Beta | 0.598 |
| Volume Avg. | 0.01M |
| Market Cap | 30.114M |
| Shares () | - |
| 52 Week Range | 1.0-20.4 |
| 1y Target Est | - |
| DCF Unlevered | ANGN DCF -> | |
|---|---|---|
| DCF Levered | ANGN LDCF -> | |
| ROE | -82.57% | Strong Sell |
| ROA | -95.59% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 0.75% | Neutral |
| P/E | -0.10 | Neutral |
| P/B | 0.76 | Buy |
Latest ANGN news
About
Download (Excel)Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D.
Healthcare
Biotechnology
NASDAQ Global Select
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.